About POGO

Press Room

Contact

On this page, you'll find our most recent press releases, popular reports and information about our experts. If you are a member of the media and want to interview an expert or need more information, please call or email the staff below.

Ari Goldberg

ARI GOLDBERG

Director of Communications

202-347-1122

agoldberg@pogo.org

Keith Rutter

Keith Rutter

COO

202-347-1122

pogo@pogo.org


Frequently Requested

Our letters and reports are frequently cited by Congress and the media. Here are links to some of our most-requested reports. If you need help finding a publication, please contact our communications staff.


Experts

POGO's experts can speak on a wide range of issues related to government oversight and accountability. Our experts are often called to testify before Congress. To arrange an interview, please contact our communications staff.

Photo of Sean Moulton

Sean Moulton

Open Government Program Manager

Sean Moulton is the Open Government Program Manager at POGO.

Photograph of Danielle Brian

Danielle Brian

Executive Director

Areas of expertise: National Security, Government Oversight, Wasteful Defense Spending, Ethics, Open Government, Whistleblower Issues

scott amey

Scott H. Amey, J.D.

General Counsel

Areas of expertise: Contract Oversight, Contractor Responsibility, the Revolving Door and Conflicts of Interest, Government Transparency

Photograph of Mandy Smithberger

Mandy Smithberger

Director, Straus Military Reform Project, CDI at POGO

Areas of expertise include National Security, Pentagon Reform

More Experts


Videos

POGO Executive Director Danielle Brian talking with Bill Moyers about how industry influence shapes laws and regulations.

How Money Rules Washington

POGO's General Counsel Scott Amey went on C-SPAN to discuss Edward Snowden and the rapid increase in private intelligence contractors.

The Rise of Intelligence Contractors

Ethan Rosenkranz will be joining POGO as a national security policy analyst.

Introducing Ethan Rosenkranz, POGO's Newest Staffer

More Videos


Latest Releases

POGO: Washington Post’s $125 billion Pentagon waste story a “perfect illustration” of longstanding problems | This story is a perfect illustration of the biggest problems affecting the Defense Department: a contractor workforce that costs too much and a fear that exposing waste will lead to cuts in defense spending. It and other reports also show there are plenty of opportunities to cut Pentagon spending and the next administration should be skeptical of anyone who tells them otherwise.

New POGO Investigation: FDA and Patient Groups Addicted to Drug Industry | A new investigation by the Project On Government Oversight (POGO) reveals the extent to which the FDA is dependent upon the pharmaceutical industry for its funding. And many of the so-called patient and consumer advocacy groups that are supposed to be a bulwark against industry influence also have strong ties to drug companies.

Joint Letter to President-Elect Trump Calls for Blind Trust for His Businesses | The Project On Government Oversight (POGO) today joined more than a dozen ethics officials and good government groups to send a letter to President-Elect Donald Trump urging him to set up a genuine blind trust, or the equivalent, for all of his business assets and investments.

Latest on the Blog

Washington Post’s $125 Billion Pentagon Waste Story is a Perfect Illustration of Longstanding Problems | "This story is a perfect illustration of the biggest problems affecting the Defense Department: a contractor workforce that costs too much and a fear that exposing waste will lead to cuts in defense spending," said Danielle Brian, POGO Executive Director.

New Roadblock for Inspectors General Access to Information | Last minute concerns over the IG Empowerment Act of 2015 may delay necessary legislation until next Congress.

FDA and Patient Groups Are Addicted to Drug Industry | A new investigation by the Project On Government Oversight (POGO) reveals the extent to which the FDA is dependent upon the pharmaceutical industry for its funding. And many of the so-called patient and consumer advocacy groups that are supposed to be a bulwark against industry influence also have strong ties to drug companies.